The development of cirrhosis in patients with chronic type B hepatitis: a prospective study
- PMID: 3371868
- DOI: 10.1002/hep.1840080310
The development of cirrhosis in patients with chronic type B hepatitis: a prospective study
Abstract
The incidence and contributing factors of cirrhosis developing in patients with chronic type B hepatitis were assessed prospectively in 684 clinicopathologically verified patients, of which 509 were HBeAg positive and 175 were anti-HBe positive at entry into the study. During an average follow-up period of 35.3 months, cirrhosis occurred 6 to 64 months after entry in 35 HBeAg-positive and 7 anti-HBe positive patients with a calculated annual incidence of 2.4 and 1.3%, respectively (p greater than 0.05). The incidence increased significantly with the increasing age at entry. Patients who had experienced (a) hepatic decompensation, (b) repeated episodes of severe acute exacerbation (with alpha-fetoprotein greater than 100 ng per ml and/or bridging hepatic necrosis), (c) severe acute exacerbation not accompanied by subsequent HBeAg seroconversion and (d) hepatitis B virus reactivation (particularly those with HBeAg reappearance) were found to develop cirrhosis much more frequently (p less than 0.001). Contrary to general belief, patients who had hepatitis delta virus superinfection and patients with chronic active hepatitis were not particularly prone to develop cirrhosis. We conclude that in addition to age factor, the extent, severity, duration, frequency and etiology of the hepatic lobular alterations are important factors for the development of cirrhosis in patients with chronic type B hepatitis.
Similar articles
-
Chronic hepatitis B. Impact of hepatitis D virus superinfection and the hepatitis B e-system on histological outcome, and correlation of the hepatitis B e-system to HBV-DNA in serum.Scand J Infect Dis Suppl. 1986;50:1-45. doi: 10.3109/inf.1986.18.suppl-50.01. Scand J Infect Dis Suppl. 1986. PMID: 3468608
-
Acute exacerbation in patients with liver cirrhosis: a clinicopathological study.Liver. 1990 Jun;10(3):177-84. doi: 10.1111/j.1600-0676.1990.tb00455.x. Liver. 1990. PMID: 1696678
-
Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients.Hepatology. 1987 Jan-Feb;7(1):20-3. doi: 10.1002/hep.1840070106. Hepatology. 1987. PMID: 2433203
-
Natural history of hepatitis B.Minerva Gastroenterol Dietol. 2005 Mar;51(1):63-75. Minerva Gastroenterol Dietol. 2005. PMID: 15756147 Review.
-
Current concepts of chronic hepatitis.Pathology. 1981 Apr;13(2):277-88. doi: 10.3109/00313028109081667. Pathology. 1981. PMID: 7019827 Review. No abstract available.
Cited by
-
Disease burden of chronic hepatitis B among immigrants in Canada.Can J Gastroenterol. 2013 Mar;27(3):137-47. doi: 10.1155/2013/924640. Can J Gastroenterol. 2013. PMID: 23516678 Free PMC article.
-
Natural history and prognostic factors for chronic hepatitis type B.Gut. 1991 Mar;32(3):294-8. doi: 10.1136/gut.32.3.294. Gut. 1991. PMID: 2013423 Free PMC article.
-
Plasma D-dimer as a novel biomarker for predicting poor outcomes in HBV-related decompensated cirrhosis.Medicine (Baltimore). 2019 Dec;98(52):e18527. doi: 10.1097/MD.0000000000018527. Medicine (Baltimore). 2019. PMID: 31876748 Free PMC article.
-
Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy.World J Gastroenterol. 2004 Mar 15;10(6):910-2. doi: 10.3748/wjg.v10.i6.910. World J Gastroenterol. 2004. PMID: 15040044 Free PMC article.
-
Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada.Pharmacoeconomics. 2020 Feb;38(2):181-192. doi: 10.1007/s40273-019-00852-y. Pharmacoeconomics. 2020. PMID: 31691902
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical